Cadrenal Therapeutics (CVKD) and The Competition Head-To-Head Review

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 952 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Cadrenal Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Profitability

This table compares Cadrenal Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,646.05%	-227.44%	-30.04%

Analyst Ratings

This is a breakdown of recent recommendations for Cadrenal Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6244	18207	42955	875	2.56

Cadrenal Therapeutics currently has a consensus price target of $3.50, indicating a potential upside of 729.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 80.71%. Given Cadrenal Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than its rivals.

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cadrenal Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.61
Cadrenal Therapeutics Competitors	$1.96 billion	$98.43 million	-4.64

Cadrenal Therapeutics’ rivals have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Cadrenal Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ rivals have a beta of 0.79, meaning that their average share price is 21% less volatile than the S&P 500.

Summary

Cadrenal Therapeutics beats its rivals on 8 of the 13 factors compared.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.